PLIANT THERAPEUTICS, INC. Proceeds from Stock Options Exercised
PLIANT THERAPEUTICS, INC. (PLRX) reported Proceeds from Stock Options Exercised of $498.00 thousand for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2022-08-08
- PLIANT THERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2022-06-30 was $447.00K, a 20.49% increase year-over-year.
- PLIANT THERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2022-03-31 was $51.00K, a 96.28% decline year-over-year.
- PLIANT THERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2021-06-30 was $371.00K, a 110.80% increase year-over-year.
- PLIANT THERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2021-03-31 was $1.37M, a 5169.23% increase year-over-year.
- PLIANT THERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2021 was $2.98M, a 575.11% increase from fiscal 2020.
- PLIANT THERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2020 was $442.00K, a 154.02% increase from fiscal 2019.
- PLIANT THERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2019 was $174.00K.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2022-06-30 | $447.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $498.00K 10-Q · filed 2022-08-08 | ||
| 2022-03-31 | $51.00K 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $2.98M 10-K · filed 2022-03-01 | |||
| 2021-06-30 | $371.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $1.74M 10-Q · filed 2022-08-08 | $1.98M derived: sum of 3 quarters · filed 2022-08-08 | $1.98M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $1.37M 10-Q · filed 2022-05-09 | $1.61M derived: sum of 2 quarters · filed 2022-05-09 | $1.61M derived: sum of 3 quarters · filed 2022-05-09 | $1.79M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $237.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $240.00K derived: sum of 2 quarters · filed 2022-03-01 | $416.00K derived: sum of 3 quarters · filed 2022-03-01 | $442.00K 10-K · filed 2022-03-01 |
| 2020-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $179.00K derived: sum of 2 quarters · filed 2021-08-09 | $205.00K 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $176.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $202.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $26.00K 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $174.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |